

Jocelyne Piret

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9145113/jocelyne-piret-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72
papers

1,849
citations

23
h-index

41
g-index

73
ext. papers

2,291
ext. citations

6.8
avg, IF

5.37
L-index

#	Paper	IF	Citations
72	Viral Interference between Respiratory Viruses.. <i>Emerging Infectious Diseases</i> , 2022 , 28, 273-281	10.2	5
71	In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.. <i>Antiviral Research</i> , 2022 , 202, 105328	10.8	
70	DNA polymerases of herpesviruses and their inhibitors. <i>The Enzymes</i> , 2021 , 50, 79-132	2.3	1
69	Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases. <i>Antiviral Research</i> , 2021 , 188, 105046	10.8	2
68	Impact of Amino Acid Substitutions in Region II and Helix K of Herpes Simplex Virus 1 and Human Cytomegalovirus DNA Polymerases on Resistance to Foscarnet. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0039021	5.9	1
67	Antiviral Drugs Against Herpesviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1322, 1-30	3.6	2
66	Microglia are involved in phagocytosis and extracellular digestion during Zika virus encephalitis in young adult immunodeficient mice. <i>Journal of Neuroinflammation</i> , 2021 , 18, 178	10.1	1
65	A novel bioluminescent herpes simplex virus 1 for in vivo monitoring of herpes simplex encephalitis. <i>Scientific Reports</i> , 2021 , 11, 18688	4.9	1
64	Zika virus and impact on male fertility 2021 , 289-298		
63	Hypersusceptibility of Human Cytomegalovirus to Foscarnet Induced by Mutations in Helices K and P of the Viral DNA Polymerase. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	4
62	Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis. <i>Clinical Microbiology Reviews</i> , 2020 , 33,	34	14
61	Modified cyclodextrins as broad-spectrum antivirals. <i>Science Advances</i> , 2020 , 6, eaax9318	14.3	87
60	An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis. <i>Journal of Virology</i> , 2020 , 94,	6.6	9
59	Pandemics Throughout History. <i>Frontiers in Microbiology</i> , 2020 , 11, 631736	5.7	89
58	Droplet Digital PCR and Immunohistochemistry Techniques to Detect Zika Virus in the Central Nervous System of Mice. <i>Methods in Molecular Biology</i> , 2020 , 2142, 41-57	1.4	2
57	Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. <i>Antiviral Research</i> , 2019 , 163, 91-105	10.8	40
56	Compartmentalization of a Multidrug-Resistant Cytomegalovirus UL54 Mutant in a Stem Cell Transplant Recipient with Encephalitis. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1302-1306	7	7

55	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. <i>Journal of Infectious Diseases</i> , 2019 , 219, 365-374	7	8
54	The recruitment of peripheral blood leukocytes to the brain is delayed in susceptible BALB/c compared to resistant C57BL/6 mice during herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , 2019 , 25, 372-383	3.9	3
53	Herpes simplex encephalitis in adult patients with MASP-2 deficiency. <i>PLoS Pathogens</i> , 2019 , 15, e1008168	6.8	14
52	Both IRF3 and especially IRF7 play a key role to orchestrate an effective cerebral inflammatory response in a mouse model of herpes simplex virus encephalitis. <i>Journal of NeuroVirology</i> , 2018 , 24, 761-788	3.8	9
51	Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. <i>Journal of General Virology</i> , 2018 , 99, 209-218	4.9	8
50	Resistance of Herpesviruses to Antiviral Agents 2018 , 233-267		
49	Herpesvirus DNA polymerases: Structures, functions and inhibitors. <i>Virus Research</i> , 2017 , 234, 177-192	6.4	41
48	DNA vaccination protects mice against Zika virus-induced damage to the testes. <i>Nature Communications</i> , 2017 , 8, 15743	17.4	76
47	Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in and Genes. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	14
46	Antiviral Drug Resistance in Herpesviruses 2017 , 87-122		2
45	Herpesvirus Resistance to Antiviral Drugs 2017 , 1185-1211		2
44	Protective role of CX3CR1 signalling in resident cells of the central nervous system during experimental herpes simplex virus encephalitis. <i>Journal of General Virology</i> , 2017 , 98, 447-460	4.9	10
43	Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus. <i>Antiviral Therapy</i> , 2016 , 21, 535-539	1.6	28
42	Novel Method Based on Real-Time Cell Analysis for Drug Susceptibility Testing of Herpes Simplex Virus and Human Cytomegalovirus. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 2120-7	9.7	23
41	Both Cerebral and Hematopoietic Deficiencies in CCR2 Result in Uncontrolled Herpes Simplex Virus Infection of the Central Nervous System in Mice. <i>PLoS ONE</i> , 2016 , 11, e0168034	3.7	7
40	Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 654-662	5.4	67
39	Valacyclovir combined with artesunate or rapamycin improves the outcome of herpes simplex virus encephalitis in mice compared to antiviral therapy alone. <i>Antiviral Research</i> , 2015 , 123, 105-13	10.8	26
38	Innate immune response during herpes simplex virus encephalitis and development of immunomodulatory strategies. <i>Reviews in Medical Virology</i> , 2015 , 25, 300-19	11.7	29

37	Infiltration Pattern of Blood Monocytes into the Central Nervous System during Experimental Herpes Simplex Virus Encephalitis. <i>PLoS ONE</i> , 2015 , 10, e0145773	3.7	23
36	Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility. <i>Journal of Virology</i> , 2015 , 89, 4636-44	6.6	11
35	Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 4043-6	9.7	19
34	Antiviral Drug Resistance in Herpesviruses 2014 , 1-32		
33	Antiviral drug resistance in herpesviruses other than cytomegalovirus. <i>Reviews in Medical Virology</i> , 2014 , 24, 186-218	11.7	101
32	Analysis of HHV-6 mutations in solid organ transplant recipients at the onset of cytomegalovirus disease and following treatment with intravenous ganciclovir or oral valganciclovir. <i>Journal of Clinical Virology</i> , 2013 , 58, 279-82	14.5	10
31	The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , 2013 , 100, 649-53	10.8	18
30	Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 1244-6	9.7	11
29	Both TRIF and IPS-1 adaptor proteins contribute to the cerebral innate immune response against herpes simplex virus 1 infection. <i>Journal of Virology</i> , 2013 , 87, 7301-8	6.6	25
28	Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays". <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2014	9.7	
27	Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 3216-24	9.7	28
26	Modulation of TLR9 response in a mouse model of herpes simplex virus encephalitis. <i>Antiviral Research</i> , 2012 , 96, 414-21	10.8	23
25	Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 459-72	5.9	344
24	A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women. <i>Contraception</i> , 2010 , 81, 79-85	2.5	17
23	Should microbicides be controlled by women or by physicians?. <i>International Journal of Infectious Diseases</i> , 2010 , 14 Suppl 3, e14-7	10.5	3
22	HIV/AIDS therapy and prevention: The two solitudes. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2009 , 20, e15-8	2.6	
21	A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon. <i>Contraception</i> , 2009 , 80, 484-92	2.5	9
20	Subchronic (26- and 52-week) toxicity and irritation studies of a novel microbicidal gel formulation containing sodium lauryl sulfate in animal models. <i>Journal of Applied Toxicology</i> , 2008 , 28, 164-74	4.1	7

19	Modulation of the in vitro activity of lysosomal phospholipase A1 by membrane lipids. <i>Chemistry and Physics of Lipids</i> , 2005 , 133, 1-15	3.7	21
18	Thermoreversible gel formulation containing sodium lauryl sulfate as a potential contraceptive device. <i>Biology of Reproduction</i> , 2003 , 69, 687-94	3.9	21
17	Sodium lauryl sulfate, a microbicide effective against enveloped and nonenveloped viruses. <i>Current Drug Targets</i> , 2002 , 3, 17-30	3	59
16	Comparative study of mechanisms of herpes simplex virus inactivation by sodium lauryl sulfate and n-lauroylsarcosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2933-42	5.9	36
15	Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1671-81	5.9	37
14	Sodium lauryl sulfate abrogates human immunodeficiency virus infectivity by affecting viral attachment. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 2229-37	5.9	22
13	Efficacies of gel formulations containing foscarnet, alone or combined with sodium lauryl sulfate, against establishment and reactivation of latent herpes simplex virus type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1030-6	5.9	5
12	Thermoreversible gel as a candidate barrier to prevent the transmission of HIV-1 and herpes simplex virus type 2. <i>Sexually Transmitted Diseases</i> , 2001 , 28, 484-91	2.4	15
11	Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 2263-70	5.9	21
10	Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 30-8	5.9	19
9	In vitro and in vivo evaluations of sodium lauryl sulfate and dextran sulfate as microbicides against herpes simplex and human immunodeficiency viruses. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 110-9	9.7	80
8	Efficacy of Gel Formulations Containing free and Liposomal Foscarnet in a Murine Model of Cutaneous HSV-1 Infection. <i>Journal of Liposome Research</i> , 1999 , 9, 181-198	6.1	6
7	Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromyclamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. <i>Toxicology and Applied Pharmacology</i> , 1999 , 156, 129-40	4.6	73
6	Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. <i>FEBS Letters</i> , 1996 , 394, 307-10	3.8	16
5	Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. <i>European Journal of Pharmacology</i> , 1996 , 314, 203-14	5.3	43
4	Interaction of the macrolide azithromycin with phospholipids. II. Biophysical and computer-aided conformational studies. <i>European Journal of Pharmacology</i> , 1996 , 314, 215-27	5.3	30
3	Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1. <i>Biochemical Pharmacology</i> , 1992 , 43, 895-8	6	12
2	Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics--I. Biochemical analysis. <i>Biochemical Pharmacology</i> , 1990 , 40, 489-97	6	32

- 1 Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition induced by aminoglycoside antibiotics--II. Conformational analysis. *Biochemical Pharmacology*, **1990**, 40, 499-506 6 17